Skip to content

Clinical study of â??SHL 1066â?? Tablet in patient with low sperm count

Evaluation of efficacy and safety of â??SHL 1066â?? in patient with low sperm count - A randomized, multicenter, double blind, placebo controlled, interventional, prospective, clinical study - NIL

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/016031
Enrollment
60
Registered
2018-10-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N461- Oligospermia

Interventions

Intervention1: SHL 1066 Tablet: It Contains Asparagus adscendens, Withania somnifera, Tribulus terrestris, Asparagus racemosus, and Emblica officinalis Dosage and Treatment Duration: Two tablets twi

Sponsors

SAVESTA LIFESCIENCES INC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Sperm count 1 million to less than 15 million/ml with normal sperm morphology 2) Subjects capable of giving written informed consent, which includes compliance with protocol. 3) Agree not to use any other treatment for erectile dysfunction (ED). 4) Willing to give specimen of semen before & at the end of the clinical trial

Exclusion criteria

Exclusion criteria: 1. Subjects having azoospermia, of aspermia, or necrospermia. 2. Subjects with clinical diagnosis of Varicocele & Hydrocele 3. Subjects with history of undescended testis 4. Subjects with inguinal hernia or other clinical condition on physical examination which may have relation to low sperm count 5. Subjects with accessory gland infection 6. Subjects with severe form of sexual dysfunction 7. Subjects with history or presence of significant alcoholism or drug abuse within the past 1 year. 8. Subjects with any clinically significant laboratory or ECG findings during screening. 9. Subjects who underwent surgery within last 4 weeks or planned major surgery within next 3 months from the date of screening. 10. Subjects who have participated in any drug research study within past 3 months. 11. Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrolment or could interfere with his participation in, and completion of the protocol

Design outcomes

Primary

MeasureTime frame
Changes in the total number of sperm cells per milliliter of seminal fluidTimepoint: Screening Visit (up to -14 days), Baseline Visit (Day 0), Visit 1 (Day 30 days), Visit 2 (Day 60 days), Visit 3 (Day 90 days)

Secondary

MeasureTime frame
1. Comparison of changes in the total number of sperm cells per ml of seminal fluid from baseline to 3 months between the groups. 2. Total Semen volume per ejaculate, percentage of total motile sperms, semen volume, semen parameters from baseline to 3 months 3. Serum total testosterone, LH, FSH, estradiol level from baseline to 3 months. 4. Erectile function domain, IIEF-IS, IIEF-OS domain from baseline to 3 months 5. Vitals and laboratory parameters from baseline to 3 months Timepoint: Screening Visit (up to -14 days), Baseline Visit (Day 0), Visit 1 (Day 30 days), Visit 2 (Day 60 days), Visit 3 (Day 90 days)

Countries

India

Contacts

Public ContactGayatri Ganu

SAVESTA LIFESCIENCES INC.

vinod.kuber@savaglobal.com7507003688

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026